Alnylam Pharmaceuticals
ALNY
278 hedge funds and large institutions have $7.86B invested in Alnylam Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 111 increasing their positions, 79 reducing their positions, and 24 closing their positions.
171% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 24
59% more call options, than puts
Call options by funds: $95.3M | Put options by funds: $59.8M
41% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 79
17% more capital invested
Capital invested by funds: $6.73B → $7.86B (+$1.13B)
17% more funds holding
Funds holding: 238 → 278 (+40)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$53.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$36.5M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$36M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$32.7M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$27.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$98.8M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$42M |
| 3 |
AWG
Alpha Wave Global
New York
|
-$39.9M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$28.9M |
| 5 |
JP Morgan Chase
New York
|
-$27.9M |
ALNY Hedge Fund Activity: Q2 2015 in Review
278 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2015, worth a combined $7.86B — up 17% from $6.73B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new ALNY positions and 24 closed out — a net gain of 41 holders — while 111 added to existing stakes and 79 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $53.7M. The largest seller was Wellington Management Group, cutting an estimated $98.8M.
- 278 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2015, up from 238 in Q1 2015.
- Funds reported $7.86B of Alnylam Pharmaceuticals stock for Q2 2015, up 17% quarter-over-quarter.
- 65 funds opened new Alnylam Pharmaceuticals positions in Q2 2015 and 24 closed out, a net change of +41 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2015 was T. Rowe Price Associates, an estimated $53.7M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2015 was Wellington Management Group, an estimated $98.8M sold.
Based on aggregated 13F filings for Q2 2015.